Who we are

At ALIGOS Therapeutics, we are a cutting-edge biotech company dedicated to discovering targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH). Our team of researchers, scientists, and medical professionals are passionate about developing innovative treatments to combat these challenging diseases.

What we Do

Our primary focus at ALIGOS Therapeutics is on research and development of antiviral therapies for chronic hepatitis B, COVID-19, and therapeutics for NASH. We utilize state-of-the-art technology and methodologies to identify and develop targeted treatments that can make a real difference in the lives of patients suffering from these conditions. Our goal is to improve patient outcomes and quality of life through groundbreaking research and innovative therapies.

In addition to our research efforts, we also work closely with regulatory agencies, healthcare providers, and patient advocacy groups to ensure that our therapies meet the highest standards of safety, efficacy, and quality. We are committed to advancing the field of antiviral therapy and making a positive impact on public health.

Why you should use us

When you choose ALIGOS Therapeutics, you are choosing a company that is at the forefront of antiviral therapy research and development. Our team of experts is dedicated to finding solutions to some of the most challenging viral diseases of our time. By partnering with us, you gain access to cutting-edge treatments that have the potential to transform the way these diseases are managed and treated.

We pride ourselves on our commitment to excellence, innovation, and collaboration. Our collaborative approach to research allows us to leverage the expertise of leading scientists, clinicians, and industry partners to accelerate the development of new therapies. When you work with ALIGOS Therapeutics, you can be confident that you are partnering with a company that is dedicated to improving patient outcomes and advancing the field of antiviral therapy.

What can you ask?

• What is the current status of your research on targeted antiviral therapies for chronic hepatitis B?
• How do your therapies for COVID-19 differ from existing treatments on the market?
• Can you provide more information on your optimized therapeutics for Nonalcoholic Steatohepatitis (NASH)?
• Are there any clinical trials currently underway for your antiviral therapies?
• How do you ensure the safety and efficacy of your treatments?
• What sets ALIGOS Therapeutics apart from other biotech companies in the field of antiviral therapy?